Table 4 Bristol knowledge questionnaire

From: The impact of integrated disease management in high-risk COPD patients in primary care

 

Integrated disease management (n = 72)

Usual care (n = 74)

Between-group difference

Baseline

12 Months

Change from baseline

Baseline

12 Months

Change from baseline

Adjusted difference (95% CI)

p-Value

Knowledge domain

Epidemiology

34.3 (20.8)

72.3 (26.0)

38.0 (26.0)

37.8 (19.6)

38.9 (21.6)

1.1 (24.9)

35.2 (28.0, 42.5)

<0.001

Etiology

54.3 (28.9)

86.0 (17.8)

31.7 (23.5)

58.9 (30.5)

60.0 (25.8)

1.1 (29.0)

28.0 (21.5, 34.4)

<0.001

Symptoms

54.3 (26.8)

85.7 (23.1)

31.4 (30.6)

55.1 (23.3)

63.0 (27.0)

7.9 (27.0)

23.7 (15.9, 31.5)

<0.001

Breathlessness

38.9 (24.3)

79.1 (26.5)

40.3 (31.5)

38.6 (19.1)

45.3 (24.9)

6.7 (25.1)

34.2 (26.0, 42.4)

<0.001

Phlegm

45.4 (26.4)

79.1 (22.2)

33.7 (25.1)

52.3 (22.5)

50.7 (29.3)

−1.6 (28.4)

32.0 (24.3, 39.7)

<0.001

Infections

37.1 (27.9)

73.7 (19.7)

36.6 (26.8)

44.1 (24.5)

46.6 (26.0)

2.5 (25.8)

29.9 (22.8, 37.0)

<0.001

Exercise

57.1 (27.5)

87.7 (21.1)

30.6 (29.0)

51.0 (23.3)

61.1 (29.0)

10.1 (33.4)

25.6 (17.3, 33.9)

<0.001

Smoking

58.0 (22.1)

73.1 (19.5)

15.1 (22.7)

58.6 (22.9)

63.3 (23.8)

4.7 (23.5)

10.5 (4.0, 17.0)

0.002

Vaccination

50.6 (25.4)

80.9 (20.3)

30.3 (21.5)

55.3 (25.1)

60.0 (23.1)

4.7 (24.8)

22.9 (16.9, 29.0)

<0.001

Inhaled bronchodilators

30.3 (28.2)

66.6 (31.3)

36.3 (28.1)

26.6 (23.6)

33.7 (25.4)

7.1 (22.5)

31.2 (23.6, 38.8)

<0.001

Antibiotics

33.1 (25.0)

66.9 (24.8)

33.7 (24.9)

34.5 (25.9)

37.3 (28.0)

2.7 (26.5)

30.6 (23.0, 38.1)

<0.001

Oral steroids

24.9 (26.9)

68.0 (34.5)

43.1 (31.7)

20.0 (26.2)

22.7 (26.5)

2.7 (30.2)

43.3 (34.4, 52.3)

<0.001

Inhaled steroids

14.6 (21.0)

54.3 (33.0)

39.7 (32.6)

11.8 (19.4)

18.9 (26.0)

7.1 (24.8)

34.5 (25.4, 43.6)

<0.001

Total

41.0 (16.2)

74.9 (18.5)

33.9 (14.2)

41.9 (13.8)

46.2 (16.6)

4.4 (15.4)

29.6 (24.9, 34.2)

<0.001